Structure Therapeutics’ stock soared toward an 18-month high in early Monday trading, after mid-stage data for its oral daily GLP-1 receptor appeared comparable to that of one of Eli Lilly’s ...

More than two months after ransomware shutdown its operations, Japanese food and beverage giant Asahi Holdings continues to suffer from back-office disruptions and was recently forced to acknowledge ...

Structure Therapeutics is developing a daily GLP-1 receptor pill called aleniglipron. Structure Therapeutics' stock soared toward an 18-month high in early Monday trading, after mid-stage data for its ...

New images of the interstellar object 3I/ATLAS have captured an astonishing, multi-jet structure, with vast plumes extending millions of kilometers into space. The discovery, observed by Frank ...

Nationwide, the Labrador Retriever holds the top spot for the most popular dog breed in the United States. Florida's top three dog breeds are also ranked within the top 10 most popular breeds across ...

In his 1960 book Theory and Design in the First Machine Age, the critic and historian Reyner Banham presciently noted a growing chasm between technological change and the capacity of designers to ...

The Eclipse Foundation's Jakarta EE Working Group has released Jakarta EE 11, the latest version of its enterprise Java platform, marking a significant step in modernizing enterprise Java development ...

Today, a brief rundown of news involving Insmed and Recursion Pharmaceuticals, as well as updates from Odyssey Therapeutics, Gilead Sciences and Novo Nordisk that you may have missed. Against the ...

(RTTNews) - Recursion Pharmaceuticals, Inc. (RXRX), a clinical-stage TechBio company, on Monday, announced that it is deprioritizing three of its clinical programs and one preclinical program ...